Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by JPPOUGET
Group name EquipeJPP
Item Type Journal Article
Title A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort
Creator Massi et al.
Author Michela Carlotta Massi
Author Francesca Gasperoni
Author Francesca Ieva
Author Anna Maria Paganoni
Author Paolo Zunino
Author Andrea Manzoni
Author Nicola Rares Franco
Author Liv Veldeman
Author Piet Ost
Author Valérie Fonteyne
Author Christopher J. Talbot
Author Tim Rattay
Author Adam Webb
Author Paul R. Symonds
Author Kerstie Johnson
Author Maarten Lambrecht
Author Karin Haustermans
Author Gert De Meerleer
Author Ben Vanneste
Author Evert Van Limbergen
Author Ananya Choudhury
Author Rebecca M. Elliott
Author Elena Sperk
Author Carsten Herskind
Author Marlon R. Veldwijk
Author Barbara Avuzzi
Author Tommaso Giandini
Author Riccardo Valdagni
Author Alessandro Cicchetti
Author David Azria
Author Marie-Pierre Farcy Jacquet
Author Barry S. Rosenstein
Author Richard G. Stock
Author Kayla Collado
Author Ana Vega
Author Miguel Elías Aguado-Barrera
Author Patricia Calvo
Author Alison M. Dunning
Author Laura Fachal
Author Sarah L. Kerns
Author Debbie Payne
Author Jenny Chang-Claude
Author Petra Seibold
Author Catharine M. L. West
Author Tiziana Rancati
Abstract Background: REQUITE (validating pREdictive models and biomarkers of radiotherapy toxicity to reduce side effects and improve QUalITy of lifE in cancer survivors) is an international prospective cohort study. The purpose of this project was to analyse a cohort of patients recruited into REQUITE using a deep learning algorithm to identify patient-specific features associated with the development of toxicity, and test the approach by attempting to validate previously published genetic risk factors. Methods: The study involved REQUITE prostate cancer patients treated with external beam radiotherapy who had complete 2-year follow-up. We used five separate late toxicity endpoints: ?grade 1 late rectal bleeding, ?grade 2 urinary frequency, ?grade 1 haematuria, ? grade 2 nocturia, ? grade 1 decreased urinary stream. Forty-three single nucleotide polymorphisms (SNPs) already reported in the literature to be associated with the toxicity endpoints were included in the analysis. No SNP had been studied before in the REQUITE cohort. Deep Sparse AutoEncoders (DSAE) were trained to recognize features (SNPs) identifying patients with no toxicity and tested on a different independent mixed population including patients without and with toxicity. Results: One thousand, four hundred and one patients were included, and toxicity rates were: rectal bleeding 11.7%, urinary frequency 4%, haematuria 5.5%, nocturia 7.8%, decreased urinary stream 17.1%. Twenty-four of the 43 SNPs that were associated with the toxicity endpoints were validated as identifying patients with toxicity. Twenty of the 24 SNPs were associated with the same toxicity endpoint as reported in the literature: 9 SNPs for urinary symptoms and 11 SNPs for overall toxicity. The other 4 SNPs were associated with a different endpoint. Conclusion: Deep learning algorithms can validate SNPs associated with toxicity after radiotherapy for prostate cancer. The method should be studied further to identify polygenic SNP risk signatures for radiotherapy toxicity. The signatures could then be included in integrated normal tissue complication probability models and tested for their ability to personalize radiotherapy treatment planning.
Publication Frontiers in Oncology
Volume 10
Pages 541281
Date 2020
Journal Abbr Front Oncol
Language eng
DOI 10.3389/fonc.2020.541281
ISSN 2234-943X
Library Catalog PubMed
Extra PMID: 33178576 PMCID: PMC7593843
Tags autoencoder, clinic, deep learning, validation
Date Added 2023/11/23 - 12:48:14
Date Modified 2024/12/15 - 11:31:04
Notes and Attachments PubMed entry (Attachment)
Texte intégral (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés